Latest Biotech News

Exelixis presented STELLAR‑303 phase III data showing that zanzalintinib plus atezolizumab reduced death risk by about 20% versus regorafenib in previously treated metastatic colorectal cancer,...

New data from multiple trials presented at ESMO and published reports reinforced circulating tumor DNA (ctDNA) as a tool to personalize adjuvant therapy. The IMvigor011/IMvigor‑derived findings...

Blackstone and TPG agreed to acquire Hologic for up to $18.3 billion in a deal that takes the diagnostics firm private; the transaction includes contingent value rights tied to breast‑health...

Anthropic unveiled 'Claude for Life Sciences', a model tailored to lab workflows and single‑cell data interrogation and announced partnerships with vendors such as 10x Genomics and Benchling to...

ESMO readouts highlighted antibody‑drug conjugates and loco‑regional delivery approaches. Investigator‑led CHOPIN results showed Delcath’s regional Chemosat plus checkpoint inhibitors tripled...

Hologic agreed to be acquired by private equity firms Blackstone and TPG in a deal valuing the company at up to $18.3 billion. The buyers will pay $76 per share plus up to $3 per share in...

Replimune said the FDA has accepted its resubmitted biologics license application for RP1, an oncolytic herpes‑based therapy combined with PD‑1 blockade, and set a target decision date of April...

Grail announced a private placement expected to raise approximately $325 million to support commercial activities, reimbursement efforts and working capital for its Galleri multi‑cancer early...

Anthropic launched Claude for Life Sciences, a model aimed at research tasks and integrations with partners like 10x Genomics and Benchling to interrogate single‑cell datasets and streamline...

Two papers published online in Nature Biotechnology report an epigenetic editing platform that enables simultaneous multi‑gene reprogramming of primary human T cells, and an integrated...

Boston Scientific agreed to acquire neuromodulation company Nalu Medical for $533 million to broaden its chronic pain portfolio. Nalu develops minimally invasive closed‑loop stimulation systems...

Bruker received FDA 510(k) clearance for new MBT Compass HT CA software, MBT FAST Shuttle US IVD sample prep and an expanded reference library for its MALDI Biotyper clinical microbiology system....

Exelixis reported detailed Phase 3 STELLAR‑303 data showing that zanzalintinib plus Roche’s Tecentriq reduced the risk of death by 20% versus standard therapy in previously treated, non‑MSI‑high...

A wave of noninvasive endometriosis tests is approaching U.S. launch, with companies analyzing biomarkers in endometrial tissue, blood, menstrual fluid and saliva to shorten a diagnosis that today...

Researchers unveiled HCS‑3DX, an AI‑driven high‑content screening platform for automated analysis of 3D multicellular structures such as spheroids and organoids, promising to speed drug discovery...

Researchers reported a new epigenetic editing platform that enables simultaneous reprogramming of multiple genes in primary human T cells, creating enhanced cellular therapies for cancer. Teams at...

Grail announced a $325 million private placement to fund commercial expansion and reimbursement efforts for its Galleri circulating tumor DNA (ctDNA) test. The financing, disclosed by Grail,...

Replimune resubmitted its biologics license application for RP1, an engineered oncolytic herpes simplex virus given with PD‑1 blockade, and the FDA has accepted the filing and set a target...

Exelixis plans an NDA submission for zanzalintinib after presenting mature overall‑survival data from the Phase 3 STELLAR‑303 trial showing a survival benefit when the TKI was combined with...

Antibody–drug conjugates (ADCs) dominated several high‑profile sessions at ESMO, with multiple companies reporting combination strategies that pair ADCs with PD‑1 inhibitors or chemotherapies to...